1-10 of 10
James R. Cerhan
Close
Sort by
Journal Articles

Defining primary refractory large B-cell lymphoma

Allison M. Bock, Raphael Mwangi, Yucai Wang, Arushi Khurana, Matthew J. Maurer, Amy Ayers, Brad S. Kahl, Peter Martin, Jonathon B. Cohen, Carla Casulo, Izidore S. Lossos, Umar Farooq, Sabarish Ayyappan, Tanner Reicks, Thomas M. Habermann, Thomas E. Witzig, Christopher R. Flowers, James R. Cerhan, Loretta J. Nastoupil, Grzegorz S. Nowakowski
Journal: Blood Advances
Blood Adv (2024) 8 (13): 3402–3415.
https://doi.org/10.1182/bloodadvances.2024012760
Published: 2024
Includes: Supplemental data
Journal Articles

Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP

Clinical Trials & Observations
Kurt S. Bantilan, Alexandra N. Smith, Matthew J. Maurer, Julie Teruya-Feldstein, Matthew J. Matasar, Alison J. Moskowitz, David J. Straus, Ariela Noy, M. Lia Palomba, Steven M. Horwitz, Paul A. Hamlin, Carol S. Portlock, James R. Cerhan, Thomas M. Habermann, Gilles A. Salles, Grzegorz S. Nowakowski, Craig H. Moskowitz, Andrew D. Zelenetz
Journal: Blood Advances
Blood Adv (2024) 8 (9): 2172–2181.
https://doi.org/10.1182/bloodadvances.2023011408
Published: 2024
Includes: Supplemental data
Journal Articles

Tumor mutational load is prognostic for progression to therapy among high-count monoclonal B-cell lymphocytosis

Clinical Trials & Observations
Geffen Kleinstern, Nicholas J. Boddicker, Daniel R. O’Brien, Cristine Allmer, Kari G. Rabe, Aaron D. Norman, Rosalie Griffin, Huihuang Yan, Tao Ma, Timothy G. Call, Laura Bruins, Sochilt Brown, Cecilia Bonolo de Campos, Curtis A. Hanson, Jose F. Leis, Wei Ding, Celine M. Vachon, Neil E. Kay, Christopher C. Oakes, Alexander S. Parker, Danielle M. Brander, J. Brice Weinberg, Richard R. Furman, Tait D. Shanafelt, James R. Cerhan, Sameer A. Parikh, Esteban Braggio, Susan L. Slager
Journal: Blood Advances
Blood Adv (2024) 8 (9): 2118–2129.
https://doi.org/10.1182/bloodadvances.2023012242
Published: 2024
Includes: Supplemental data
Journal Articles

Differential prognosis of single and multiple TP53 abnormalities in high-count MBL and untreated CLL

Rosalie Griffin, Julia E. Wiedmeier-Nutor, Sameer A. Parikh, Chantal E. McCabe, Daniel R. O'Brien, Nicholas J. Boddicker, Geffen Kleinstern, Kari G. Rabe, Laura Bruins, Sochilt Brown, Cecilia Bonolo de Campos, Wei Ding, Jose F. Leis, Paul J. Hampel, Timothy G. Call, Daniel L. Van Dyke, Neil E. Kay, James R. Cerhan, Huihuang Yan, Susan L. Slager, Esteban Braggio
Journal: Blood Advances
Blood Adv (2023) 7 (13): 3169–3179.
https://doi.org/10.1182/bloodadvances.2022009040
Published: 2023
Includes: Supplemental data
Journal Articles

Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma

Clinical Trials & Observations
Narendranath Epperla, Jeffrey Switchenko, Veronika Bachanova, James N. Gerson, Stefan K. Barta, Max J. Gordon, Alexey V. Danilov, Natalie S. Grover, Stephanie Mathews, Madelyn Burkart, Reem Karmali, Yazeed Sawalha, Brian T. Hill, Nilanjan Ghosh, Steven I. Park, David A. Bond, Mehdi Hamadani, Timothy S. Fenske, Peter Martin, Mary-Kate Malecek, Brad S. Kahl, Christopher R. Flowers, Brian K. Link, Lawrence D. Kaplan, David J. Inwards, Andrew L. Feldman, Eric D. Hsi, Kami Maddocks, Kristie A. Blum, Nancy L. Bartlett, James R. Cerhan, John P. Leonard, Thomas M. Habermann, Matthew J. Maurer, Jonathon B. Cohen
Journal: Blood Advances
Blood Adv (2023) 7 (11): 2287–2296.
https://doi.org/10.1182/bloodadvances.2022009225
Published: 2023
Includes: Supplemental data
Journal Articles

Increasing tissue requirements in lymphoma trials may exclude patients with high-risk disease or worse prognosis

Clinical Trials & Observations
Sanjal H. Desai, Raphael Mwangi, Wern Lynn Ng, Rebecca L. King, Matthew J. Maurer, James R. Cerhan, Andrew L. Feldman, Umar Farooq, Eric Mou, Thomas M. Habermann, Carrie A. Thompson, Yucai Wang, Thomas E. Witzig, Grzegorz S. Nowakowski
Journal: Blood Advances
Blood Adv (2022) 6 (24): 6180–6186.
https://doi.org/10.1182/bloodadvances.2022007569
Published: 2022
Includes: Supplemental data
Journal Articles

Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study

Aung M. Tun, Arushi Khurana, Raphael Mwangi, Brian K. Link, Yucai Wang, Andrew L. Feldman, Carrie A. Thompson, Anne J. Novak, Jose C. Villasboas, Gita Thanarajasingam, Umar Farooq, Sergei Syrbu, Grzegorz S. Nowakowski, Thomas E. Witzig, Stephen M. Ansell, Lisa M. Rimsza, James R. Cerhan, Thomas M. Habermann, Matthew J. Maurer
Journal: Blood Advances
Blood Adv (2022) 6 (17): 5210–5221.
https://doi.org/10.1182/bloodadvances.2022007990
Published: 2022
Includes: Supplemental data
Journal Articles

Evaluating the impact of eligibility criteria in first-line clinical trials for follicular lymphoma: a MER/LEO cohort analysis

Danny Luan, Tolulope Fatola, Ahmed Toure, Christopher R. Flowers, Brian Link, Jonathan W. Friedberg, Jonathon B. Cohen, Brad Kahl, Izidore S. Lossos, Loretta Nastoupil, Matthew J. Maurer, James R. Cerhan, Peter Martin
Journal: Blood Advances
Blood Adv (2022) 6 (15): 4413–4423.
https://doi.org/10.1182/bloodadvances.2022007687
Published: 2022
Includes: Supplemental data
Journal Articles

Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes

Clinical Trials & Observations
Alessia Castellino, Yucai Wang, Melissa C. Larson, Matthew J. Maurer, Brian K. Link, Umar Farooq, Andrew L. Feldman, Sergei I. Syrbu, Thomas M. Habermann, Jonas Paludo, David J. Inwards, Thomas E. Witzig, Stephen M. Ansell, Cristine Allmer, Susan L. Slager, Jonathon B. Cohen, Peter Martin, James R. Cerhan, Grzegorz S. Nowakowski
Journal: Blood Advances
Blood Adv (2022) 6 (4): 1350–1360.
https://doi.org/10.1182/bloodadvances.2021005715
Published: 2022
Includes: Supplemental data
Journal Articles

Early progression of disease in follicular lymphoma is a robust correlate but not a surrogate for overall survival

Clinical Trials & Observations
Emmanuel Bachy, James R. Cerhan, Gilles Salles
Journal: Blood Advances
Blood Adv (2021) 5 (6): 1729–1732.
https://doi.org/10.1182/bloodadvances.2020003797
Published: 2021
Includes: Supplemental data